NCT05321069: A reported trial by Boehringer Ingelheim
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05321069 |
|---|---|
| Title | A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 6, 2022 |
| Completion date | Aug. 16, 2024 |
| Required reporting date | Aug. 16, 2025, midnight |
| Actual reporting date | Aug. 13, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |